Genomic Features of Response to Combination Immunotherapy in Lung Cancer

Cancer Cell
Martin Früh, Solange Peters

Abstract

In this issue of Cancer Cell, Hellmann et al. describe in two clinical trials the importance of tumor mutational burden as an independent predictive marker for outcomes with combination nivolumab plus ipilimumab as first-line therapy in metastatic non-small-cell lung cancer and in relapsed small-cell lung cancer.

Associated Clinical Trials

Nov 10, 2020·Maria Chiara Bonini

Citations

Dec 28, 2018·The Journal of Clinical Investigation·Roman M ChabanonSophie Postel-Vinay
Sep 5, 2019·International Journal of Molecular Sciences·Changzheng WangXiuqing Zhang
Mar 10, 2020·Archives of Pathology & Laboratory Medicine·Irina SobolAlain C Borczuk
Mar 16, 2021·Expert Review of Anticancer Therapy·Erika RijavecFrancesco Grossi
Apr 5, 2021·International Immunopharmacology·Yuansheng ZhengWei Jiang
Jul 1, 2020·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Kate D Sutherland, Joseph H A Vissers

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Genomics (Keystone)

Cancer genomics approaches employ high-throughput technologies to identify the complete catalog of somatic alterations that characterize the genome, transcriptome and epigenome of cohorts of tumor samples. Discover the latest research using such technologies in this feed.

Related Papers

The Lancet Oncology
Yangqiu Li, Yi-Long Wu
Journal of the Advanced Practitioner in Oncology
Andrea Deel
© 2022 Meta ULC. All rights reserved